NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Biotechnology · CAD

Fennec Pharmaceuticals Inc. (FRX.TO) Stock Analysis

Fennec Pharmaceuticals Inc. (FRX.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.

FRX.TO

CA$17.42

+CA$0.13 (+0.75%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FRX.TO with… →

FRX.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$16.33
Previous Close
CA$17.29
Day's Range
16.33–17.42
52-Week Range
7.59–17.64
Volume
300
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.10
Valuation
Market Cap
CA$610.87M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.16
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
10.32
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.17
Financials (FY)
Revenue (FY)
CA$44.64M−6.09%
Net Income (FY)
−CA$9.74M
Profit marginThe share of revenue left as profit after all costs and taxes.
−5.49%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
35.07M
1-Year Return
+40.26%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
682

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

FRX.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+64.34%
2025+19.50%
2024−41.49%
2023+15.81%
2022+133.75%
2021−38.39%
2020+7.57%
2019−1.17%
2018−31.55%
2017+378.54%
2016 (partial year)−6.79%

As of September 4, 2026.

FRX.TO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025CA$44.64M−CA$9.74M−21.8%
2024CA$47.54M−CA$436.00K−0.9%
2023CA$21.25M−CA$16.05M−75.5%
2022CA$1.54M−CA$23.71M−1544.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$44.64MCA$40.88M−CA$6.35M−CA$9.74M−21.8%
2024CA$47.54MCA$44.35MCA$2.48M−CA$436.00K−0.9%
2023CA$21.25MCA$19.99M−CA$13.06M−CA$16.05M−75.5%
2022CA$1.54MCA$1.45M−CA$22.74M−CA$23.71M−1544.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FRX.TO Valuation vs Biotechnology Median

Median of 656 stocks
MetricFRX.TOBiotechnology medianvs median
P/S ratio10.3215.2632% below
Profit margin−5.49%0.00%5.5 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Fennec Pharmaceuticals Inc. (FRX.TO) at CA$610.87M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 35.

Over the past 52 weeks the price has ranged from CA$7.59 to CA$17.64. The most recent close on file for FRX.TO is CA$17.42, dated September 4, 2026. That is +CA$0.13 (+0.75%) against the previous close. The latest close sits 129.51% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to CA$44.64M. Against the prior fiscal year total of CA$47.54M, that is a change of −6.09%. The same year closed with a net loss of CA$9.74M. The reported profit margin is −5.49%. That is 5.5 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.17.

Across the 4 fiscal years on file, revenue moves from CA$1.54M in 2022 to CA$44.64M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 13.16. The price-to-sales ratio is 10.32. On price-to-sales that is 32.42% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.1. Annualized volatility over the trailing 10 years is 65.73%. The trailing one-year price return is +40.26%. Across 10 years the annualized return works out at +20.58%.

Growth & Income

No dividend is on file for FRX.TO.

The strongest complete calendar year on file is 2017 at +378.54%; the weakest is 2024 at −41.49%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is +64.34% year to date.

Peer Comparison

Fennec Pharmaceuticals Inc. (FRX.TO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Fennec Pharmaceuticals Inc. FRX.TO CA$610.87M —
Vertex Pharmaceuticals Incorporated VRTX CA$138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN CA$85.22B 20.5
argenx SE ARGX CA$64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Fennec Pharmaceuticals Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Visit website →